Provided by Tiger Trade Technology Pte. Ltd.

KEYMED BIO-B

75.600
-1.900-2.45%
Volume:2.16M
Turnover:166.61M
Market Cap:22.60B
PE:-39.58
High:80.400
Open:77.500
Low:75.000
Close:77.500
52wk High:89.750
52wk Low:44.660
Shares:299.00M
HK Float Shares:299.00M
Volume Ratio:2.55
T/O Rate:0.72%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.910
ROE:21.49%
ROA:-8.24%
PB:4.82
PE(LYR):-39.58
PS:23.14

Loading ...

HK Movers | Biomedical Stocks Rally; REMEGEN, WUXI XDC and KEYMED BIO-B Surge Over 8%

Tiger Newspress
·
Jul 20

Movement Alert|Keymed Biosciences Rises 7.1% in Regular Trading, Profit Alert and Sector-Wide Institutional Buying Boost Shares

Market Focus
·
Jul 20

Movement Alert|Keymed Biosciences Drops 5.12% in Regular Trading, Biotech Sector Broadly Weakens After Prior Catalysts Priced In

Market Focus
·
Jul 17

Keymed Biosciences Inc. (HKG:2162) About To Shift From Loss To Profit

Simply Wall St.
·
Jul 16

Keymed Biosciences Expects H1 Profit at Least RMB 1.2 Billion

Reuters
·
Jul 15

KEYMED BIO-B Shares Surge Over 9% Intraday as Dual-Antibody Drug CM512 Designated for Breakthrough Therapy

Stock News
·
Jul 15

Movement Alert|Keymed Biosciences Rises 5.08% in Regular Trading, Core Product Included in New National Essential Drug List with Multiple Brokerages Maintaining Buy Ratings

Market Focus
·
Jul 15

GTHT Securities Initiates Coverage on KEYMED BIO-B with Buy Rating and HK$138.91 Price Target

Deep News
·
Jul 09

Guotai Haitong Securities Initiates Coverage on KEYMED BIO-B with Buy Rating and HK$138.91 Price Target

Stock News
·
Jul 09

Innovative Drug Sector Maintains Upward Momentum on Favorable Regulatory Developments and Accelerating Internationalization

Stock News
·
Jul 06

Hong Kong Innovative Drug Stocks Jump With HAIXI PHARMA and INNOCARE up 7%; KEYMED up 5%, REMEGEN up 4%

Tiger Newspress
·
Jul 06

Movement Alert|Keymed Biosciences Rises 5.16% in Regular Trading, Dual Insurance Directory Policy and Two New Drug Clinical Approvals Fuel Gains

Market Focus
·
Jul 06

Movement Alert|Keymed Biosciences Rises 5.34% in Regular Trading, Dual Insurance Directory Policy and Long-Acting AD Track Valuation Reshaping Drive Continued Rally

Market Focus
·
Jul 03

Movement Alert|Keymed Biosciences Rises 9.4% in Regular Trading, Dual Medical Insurance Directory Policy Catalyzes Long-Acting AD Track Revaluation

Market Focus
·
Jul 02

Movement Alert|Keymed Biosciences Rises 5.46% in Regular Trading, AbbVie USD 10.9 Billion Apogee Acquisition Continues to Catalyze Long-Acting AD Track Valuation

Market Focus
·
Jun 29

Keymed Biosciences: All AGM Resolutions Secure Approval; Shareholders Signal Overwhelming Confidence

Bulletin Express
·
Jun 26

Keymed Biosciences Shareholders Approved All AGM Resolutions in Poll Vote

Reuters
·
Jun 26

Movement Alert|Keymed Biosciences Intraday Rise 5.65%, AbbVie Billion-Dollar Apogee Acquisition Continues to Catalyze Long-Acting AD Pipeline

Market Focus
·
Jun 26

Hong Kong Stocks Surge: Innovative Drug Sector Rallies on Regulatory Report and New Foreign Investment Policies

Stock News
·
Jun 23

Jinrui Securities Maintains Buy Rating on KEYMED BIO-B, Citing Validation of Long-Acting AD Drug Value by Major Pharma Deal

Stock News
·
Jun 23